News on protein analysis, clinical proteomics, biomarkers in genetics, genomics, and molecular diagnostics.
A review by Max Planck researcher Matthias Mann and colleagues suggests that improved mass spec performance could enable more effective plasma marker discovery.
A University of Graz team used a protein interaction-based proteogenomic approach to study the effect of mutations on the eight components of the BBSome complex.
The researchers are now working with Chinese collaborators to license the markers in that country and launch clinical studies of their utility for lung cancer detection.
The researchers combined different proteomic methods to explore the activity of the ALK inhibitor ceritinib and identify potential combination therapies.
The company will use the funds to refine a nanoparticle-based immunoenrichment approach to simplifying sample separations up front of mass spec analysis.
The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.
Kaiser Health News reports that gene therapies could cost more than a million dollars.
Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.
In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.